English
简体中文
Total: £ 56.28
Published Date: 2025-09-25 | Pages: 104 | Tables: 103 | Pharma & Healthcare
The global Follicular Lymphoma Drugs market size was US$ 1972 million in 2024 and is forecast to a readjusted size of US$ 3227 million by 2031 with a CAGR of 7.4% during the forecast period 2025-2031.
Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma.Drugs for Follicular lymphoma are Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, etc.
The follicular lymphoma drugs market is primarily driven by the increasing prevalence of follicular lymphoma (FL), a common and slow-growing form of non-Hodgkin lymphoma. As the global population ages, the incidence of FL is expected to rise, which boosts demand for effective treatments. Additionally, recent advancements in targeted therapies, including monoclonal antibodies like rituximab and the development of novel small molecules, have significantly improved patient outcomes and survival rates. The growing adoption of combination therapies, such as chemotherapy paired with targeted treatments or immunotherapies, has further expanded treatment options and contributed to the market's growth. The emergence of personalized medicine also enhances the potential for more tailored, effective therapies.
On the other hand, the follicular lymphoma drugs market faces challenges, including the high cost of cutting-edge therapies. Treatments such as CAR-T cell therapy and novel biologics, while effective, can be expensive and limit patient access, particularly in lower-income regions. Additionally, although FL is typically slow-growing, it is also highly recurrent, requiring long-term management and monitoring, which can strain healthcare systems. The risk of resistance to existing therapies, along with concerns over the long-term side effects of certain treatments, further complicates the landscape. Regulatory hurdles for the approval of new drugs, along with the need for ongoing research into optimizing treatment regimens, present further challenges in meeting the diverse needs of FL patients.
Global core follicular lymphoma drugs players include Roche, Teva and Bayer etc. The Top3 companies hold a share about 57%. North America is the largest market, with a share about 58%, followed by Europe and Asia Pacific with the share about 21% and 20%.
The global Follicular Lymphoma Drugs market is strategically segmented by company, region (country), by Type, and by Administration Route. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Administration Route for 2020-2031.
Market Segmentation
By Company:
Roche
Gilead Sciences
Beigene
Bayer
Secura Bio
Epizyme
Eisai
Acrotech Biopharma
Teva
Eagle Pharmaceuticals
MundiPharma
Pfizer
Novartis
Bristol-Myers Squibb
JW Therapeutics
FOSUNKite
By Type: (Dominant Segment vs High-Margin Innovation)
Anti-CD20 mAbs
Chemotherapy Agents
Kinase Inhibitor
Others
By Application: (Core Demand Driver vs Emerging Opportunity)
Injection
Oral
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Roche in Europe)
- Emerging Product Trends: Anti-CD20 mAbs adoption vs. Chemotherapy Agents premiumization
- Demand-Side Dynamics: Injection growth in China vs. Oral potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
(Additional regions can be customized based on client needs.)
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Follicular Lymphoma Drugs market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Chemotherapy Agents in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Oral in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Follicular Lymphoma Drugs value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 Anti-CD20 mAbs
1.2.3 Chemotherapy Agents
1.2.4 Kinase Inhibitor
1.2.5 Others
1.3 Market by Administration Route
1.3.1 Global Market Share by Administration Route: 2020 VS 2024 VS 2031
1.3.2 Injection
1.3.3 Oral
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Follicular Lymphoma Drugs Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Follicular Lymphoma Drugs Revenue Market Share by Region (2020-2025)
2.4 Global Follicular Lymphoma Drugs Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Follicular Lymphoma Drugs Market Size and Prospective (2020-2031)
2.5.2 Europe Follicular Lymphoma Drugs Market Size and Prospective (2020-2031)
2.5.3 China Follicular Lymphoma Drugs Market Size and Prospective (2020-2031)
2.5.4 Japan Follicular Lymphoma Drugs Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Follicular Lymphoma Drugs Historic Market Size by Type (2020-2025)
3.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Type (2026-2031)
3.3 Different Types Follicular Lymphoma Drugs Representative Players
4 Breakdown Data by Administration Route
4.1 Global Follicular Lymphoma Drugs Historic Market Size by Administration Route (2020-2025)
4.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Administration Route (2026-2031)
4.3 New Sources of Growth in Follicular Lymphoma Drugs Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Follicular Lymphoma Drugs Players by Revenue (2020-2025)
5.1.2 Global Follicular Lymphoma Drugs Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Follicular Lymphoma Drugs Revenue
5.4 Global Follicular Lymphoma Drugs Market Concentration Analysis
5.4.1 Global Follicular Lymphoma Drugs Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Follicular Lymphoma Drugs Revenue in 2024
5.5 Global Key Players of Follicular Lymphoma Drugs Head office and Area Served
5.6 Global Key Players of Follicular Lymphoma Drugs, Product and Application
5.7 Global Key Players of Follicular Lymphoma Drugs, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Follicular Lymphoma Drugs Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Follicular Lymphoma Drugs Market Size by Type (2020-2025)
6.1.2.2 North America Follicular Lymphoma Drugs Market Share by Type (2020-2025)
6.1.3 North America Market Size by Administration Route
6.1.3.1 North America Follicular Lymphoma Drugs Market Size by Administration Route (2020-2025)
6.1.3.2 North America Follicular Lymphoma Drugs Market Share by Administration Route (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Follicular Lymphoma Drugs Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Follicular Lymphoma Drugs Market Size by Type (2020-2025)
6.2.2.2 Europe Follicular Lymphoma Drugs Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Administration Route
6.2.3.1 Europe Follicular Lymphoma Drugs Market Size by Administration Route (2020-2025)
6.2.3.2 Europe Follicular Lymphoma Drugs Market Share by Administration Route (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments and Downstream
6.3.1 China Follicular Lymphoma Drugs Revenue by Company (2020-2025)
6.3.2 China Market Size by Type
6.3.2.1 China Follicular Lymphoma Drugs Market Size by Type (2020-2025)
6.3.2.2 China Follicular Lymphoma Drugs Market Share by Type (2020-2025)
6.3.3 China Market Size by Administration Route
6.3.3.1 China Follicular Lymphoma Drugs Market Size by Administration Route (2020-2025)
6.3.3.2 China Follicular Lymphoma Drugs Market Share by Administration Route (2020-2025)
6.3.4 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments and Downstream
6.4.1 Japan Follicular Lymphoma Drugs Revenue by Company (2020-2025)
6.4.2 Japan Market Size by Type
6.4.2.1 Japan Follicular Lymphoma Drugs Market Size by Type (2020-2025)
6.4.2.2 Japan Follicular Lymphoma Drugs Market Share by Type (2020-2025)
6.4.3 Japan Market Size by Administration Route
6.4.3.1 Japan Follicular Lymphoma Drugs Market Size by Administration Route (2020-2025)
6.4.3.2 Japan Follicular Lymphoma Drugs Market Share by Administration Route (2020-2025)
6.4.4 Japan Market Trend and Opportunities
7 Key Players Profiles
7.1 Roche
7.1.1 Roche Company Details
7.1.2 Roche Business Overview
7.1.3 Roche Follicular Lymphoma Drugs Introduction
7.1.4 Roche Revenue in Follicular Lymphoma Drugs Business (2020-2025)
7.1.5 Roche Recent Development
7.2 Gilead Sciences
7.2.1 Gilead Sciences Company Details
7.2.2 Gilead Sciences Business Overview
7.2.3 Gilead Sciences Follicular Lymphoma Drugs Introduction
7.2.4 Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (2020-2025)
7.2.5 Gilead Sciences Recent Development
7.3 Beigene
7.3.1 Beigene Company Details
7.3.2 Beigene Business Overview
7.3.3 Beigene Follicular Lymphoma Drugs Introduction
7.3.4 Beigene Revenue in Follicular Lymphoma Drugs Business (2020-2025)
7.3.5 Beigene Recent Development
7.4 Bayer
7.4.1 Bayer Company Details
7.4.2 Bayer Business Overview
7.4.3 Bayer Follicular Lymphoma Drugs Introduction
7.4.4 Bayer Revenue in Follicular Lymphoma Drugs Business (2020-2025)
7.4.5 Bayer Recent Development
7.5 Secura Bio
7.5.1 Secura Bio Company Details
7.5.2 Secura Bio Business Overview
7.5.3 Secura Bio Follicular Lymphoma Drugs Introduction
7.5.4 Secura Bio Revenue in Follicular Lymphoma Drugs Business (2020-2025)
7.5.5 Secura Bio Recent Development
7.6 Epizyme
7.6.1 Epizyme Company Details
7.6.2 Epizyme Business Overview
7.6.3 Epizyme Follicular Lymphoma Drugs Introduction
7.6.4 Epizyme Revenue in Follicular Lymphoma Drugs Business (2020-2025)
7.6.5 Epizyme Recent Development
7.7 Eisai
7.7.1 Eisai Company Details
7.7.2 Eisai Business Overview
7.7.3 Eisai Follicular Lymphoma Drugs Introduction
7.7.4 Eisai Revenue in Follicular Lymphoma Drugs Business (2020-2025)
7.7.5 Eisai Recent Development
7.8 Acrotech Biopharma
7.8.1 Acrotech Biopharma Company Details
7.8.2 Acrotech Biopharma Business Overview
7.8.3 Acrotech Biopharma Follicular Lymphoma Drugs Introduction
7.8.4 Acrotech Biopharma Revenue in Follicular Lymphoma Drugs Business (2020-2025)
7.8.5 Acrotech Biopharma Recent Development
7.9 Teva
7.9.1 Teva Company Details
7.9.2 Teva Business Overview
7.9.3 Teva Follicular Lymphoma Drugs Introduction
7.9.4 Teva Revenue in Follicular Lymphoma Drugs Business (2020-2025)
7.9.5 Teva Recent Development
7.10 Eagle Pharmaceuticals
7.10.1 Eagle Pharmaceuticals Company Details
7.10.2 Eagle Pharmaceuticals Business Overview
7.10.3 Eagle Pharmaceuticals Follicular Lymphoma Drugs Introduction
7.10.4 Eagle Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (2020-2025)
7.10.5 Eagle Pharmaceuticals Recent Development
7.11 MundiPharma
7.11.1 MundiPharma Company Details
7.11.2 MundiPharma Business Overview
7.11.3 MundiPharma Follicular Lymphoma Drugs Introduction
7.11.4 MundiPharma Revenue in Follicular Lymphoma Drugs Business (2020-2025)
7.11.5 MundiPharma Recent Development
7.12 Pfizer
7.12.1 Pfizer Company Details
7.12.2 Pfizer Business Overview
7.12.3 Pfizer Follicular Lymphoma Drugs Introduction
7.12.4 Pfizer Revenue in Follicular Lymphoma Drugs Business (2020-2025)
7.12.5 Pfizer Recent Development
7.13 Novartis
7.13.1 Novartis Company Details
7.13.2 Novartis Business Overview
7.13.3 Novartis Follicular Lymphoma Drugs Introduction
7.13.4 Novartis Revenue in Follicular Lymphoma Drugs Business (2020-2025)
7.13.5 Novartis Recent Development
7.14 Bristol-Myers Squibb
7.14.1 Bristol-Myers Squibb Company Details
7.14.2 Bristol-Myers Squibb Business Overview
7.14.3 Bristol-Myers Squibb Follicular Lymphoma Drugs Introduction
7.14.4 Bristol-Myers Squibb Revenue in Follicular Lymphoma Drugs Business (2020-2025)
7.14.5 Bristol-Myers Squibb Recent Development
7.15 JW Therapeutics
7.15.1 JW Therapeutics Company Details
7.15.2 JW Therapeutics Business Overview
7.15.3 JW Therapeutics Follicular Lymphoma Drugs Introduction
7.15.4 JW Therapeutics Revenue in Follicular Lymphoma Drugs Business (2020-2025)
7.15.5 JW Therapeutics Recent Development
7.16 FOSUNKite
7.16.1 FOSUNKite Company Details
7.16.2 FOSUNKite Business Overview
7.16.3 FOSUNKite Follicular Lymphoma Drugs Introduction
7.16.4 FOSUNKite Revenue in Follicular Lymphoma Drugs Business (2020-2025)
7.16.5 FOSUNKite Recent Development
8 Follicular Lymphoma Drugs Market Dynamics
8.1 Follicular Lymphoma Drugs Industry Trends
8.2 Follicular Lymphoma Drugs Market Drivers
8.3 Follicular Lymphoma Drugs Market Challenges
8.4 Follicular Lymphoma Drugs Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Global Follicular Lymphoma Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Follicular Lymphoma Drugs Market Size Growth by Administration Route (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market Follicular Lymphoma Drugs Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Follicular Lymphoma Drugs Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global Follicular Lymphoma Drugs Revenue Share by Region (2020-2025)
Table 6. Global Follicular Lymphoma Drugs Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global Follicular Lymphoma Drugs Revenue Share Forecast by Region (2026-2031)
Table 8. Global Follicular Lymphoma Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global Follicular Lymphoma Drugs Revenue Market Share by Type (2020-2025)
Table 10. Global Follicular Lymphoma Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global Follicular Lymphoma Drugs Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global Follicular Lymphoma Drugs Market Size by Administration Route (2020-2025) & (US$ Million)
Table 14. Global Follicular Lymphoma Drugs Revenue Market Share by Administration Route (2020-2025)
Table 15. Global Follicular Lymphoma Drugs Forecasted Market Size by Administration Route (2026-2031) & (US$ Million)
Table 16. Global Follicular Lymphoma Drugs Revenue Market Share by Administration Route (2026-2031)
Table 17. New Sources of Growth in Follicular Lymphoma Drugs Application
Table 18. Global Follicular Lymphoma Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Follicular Lymphoma Drugs Market Share by Players (2020-2025)
Table 20. Global Top Follicular Lymphoma Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Follicular Lymphoma Drugs as of 2024)
Table 21. Ranking of Global Top Follicular Lymphoma Drugs Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Follicular Lymphoma Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Follicular Lymphoma Drugs, Headquarters and Area Served
Table 24. Global Key Players of Follicular Lymphoma Drugs, Product and Application
Table 25. Global Key Players of Follicular Lymphoma Drugs, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Follicular Lymphoma Drugs Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America Follicular Lymphoma Drugs Revenue Market Share by Company (2020-2025)
Table 29. North America Follicular Lymphoma Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America Follicular Lymphoma Drugs Market Size by Administration Route (2020-2025) & (US$ Million)
Table 31. Europe Follicular Lymphoma Drugs Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe Follicular Lymphoma Drugs Revenue Market Share by Company (2020-2025)
Table 33. Europe Follicular Lymphoma Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe Follicular Lymphoma Drugs Market Size by Administration Route (2020-2025) & (US$ Million)
Table 35. China Follicular Lymphoma Drugs Revenue by Company (2020-2025) & (US$ Million)
Table 36. China Follicular Lymphoma Drugs Revenue Market Share by Company (2020-2025)
Table 37. China Follicular Lymphoma Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 38. China Follicular Lymphoma Drugs Market Size by Administration Route (2020-2025) & (US$ Million)
Table 39. Japan Follicular Lymphoma Drugs Revenue by Company (2020-2025) & (US$ Million)
Table 40. Japan Follicular Lymphoma Drugs Revenue Market Share by Company (2020-2025)
Table 41. Japan Follicular Lymphoma Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 42. Japan Follicular Lymphoma Drugs Market Size by Administration Route (2020-2025) & (US$ Million)
Table 43. Roche Company Details
Table 44. Roche Business Overview
Table 45. Roche Follicular Lymphoma Drugs Product
Table 46. Roche Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 47. Roche Recent Development
Table 48. Gilead Sciences Company Details
Table 49. Gilead Sciences Business Overview
Table 50. Gilead Sciences Follicular Lymphoma Drugs Product
Table 51. Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 52. Gilead Sciences Recent Development
Table 53. Beigene Company Details
Table 54. Beigene Business Overview
Table 55. Beigene Follicular Lymphoma Drugs Product
Table 56. Beigene Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 57. Beigene Recent Development
Table 58. Bayer Company Details
Table 59. Bayer Business Overview
Table 60. Bayer Follicular Lymphoma Drugs Product
Table 61. Bayer Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 62. Bayer Recent Development
Table 63. Secura Bio Company Details
Table 64. Secura Bio Business Overview
Table 65. Secura Bio Follicular Lymphoma Drugs Product
Table 66. Secura Bio Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 67. Secura Bio Recent Development
Table 68. Epizyme Company Details
Table 69. Epizyme Business Overview
Table 70. Epizyme Follicular Lymphoma Drugs Product
Table 71. Epizyme Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 72. Epizyme Recent Development
Table 73. Eisai Company Details
Table 74. Eisai Business Overview
Table 75. Eisai Follicular Lymphoma Drugs Product
Table 76. Eisai Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 77. Eisai Recent Development
Table 78. Acrotech Biopharma Company Details
Table 79. Acrotech Biopharma Business Overview
Table 80. Acrotech Biopharma Follicular Lymphoma Drugs Product
Table 81. Acrotech Biopharma Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 82. Acrotech Biopharma Recent Development
Table 83. Teva Company Details
Table 84. Teva Business Overview
Table 85. Teva Follicular Lymphoma Drugs Product
Table 86. Teva Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 87. Teva Recent Development
Table 88. Eagle Pharmaceuticals Company Details
Table 89. Eagle Pharmaceuticals Business Overview
Table 90. Eagle Pharmaceuticals Follicular Lymphoma Drugs Product
Table 91. Eagle Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 92. Eagle Pharmaceuticals Recent Development
Table 93. MundiPharma Company Details
Table 94. MundiPharma Business Overview
Table 95. MundiPharma Follicular Lymphoma Drugs Product
Table 96. MundiPharma Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 97. MundiPharma Recent Development
Table 98. Pfizer Company Details
Table 99. Pfizer Business Overview
Table 100. Pfizer Follicular Lymphoma Drugs Product
Table 101. Pfizer Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 102. Pfizer Recent Development
Table 103. Novartis Company Details
Table 104. Novartis Business Overview
Table 105. Novartis Follicular Lymphoma Drugs Product
Table 106. Novartis Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 107. Novartis Recent Development
Table 108. Bristol-Myers Squibb Company Details
Table 109. Bristol-Myers Squibb Business Overview
Table 110. Bristol-Myers Squibb Follicular Lymphoma Drugs Product
Table 111. Bristol-Myers Squibb Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 112. Bristol-Myers Squibb Recent Development
Table 113. JW Therapeutics Company Details
Table 114. JW Therapeutics Business Overview
Table 115. JW Therapeutics Follicular Lymphoma Drugs Product
Table 116. JW Therapeutics Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 117. JW Therapeutics Recent Development
Table 118. FOSUNKite Company Details
Table 119. FOSUNKite Business Overview
Table 120. FOSUNKite Follicular Lymphoma Drugs Product
Table 121. FOSUNKite Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 122. FOSUNKite Recent Development
Table 123. Follicular Lymphoma Drugs Market Trends
Table 124. Follicular Lymphoma Drugs Market Drivers
Table 125. Follicular Lymphoma Drugs Market Challenges
Table 126. Follicular Lymphoma Drugs Market Restraints
Table 127. Research Programs/Design for This Report
Table 128. Key Data Information from Secondary Sources
Table 129. Key Data Information from Primary Sources
List of Figures
Figure 1. Follicular Lymphoma Drugs Product Picture
Figure 2. Global Follicular Lymphoma Drugs Market Share by Type: 2024 VS 2031
Figure 3. Anti-CD20 mAbs Features
Figure 4. Chemotherapy Agents Features
Figure 5. Kinase Inhibitor Features
Figure 6. Others Features
Figure 7. Global Follicular Lymphoma Drugs Market Share by Administration Route: 2024 VS 2031
Figure 8. Injection
Figure 9. Oral
Figure 10. Follicular Lymphoma Drugs Report Years Considered
Figure 11. Global Follicular Lymphoma Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 12. Global Follicular Lymphoma Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Follicular Lymphoma Drugs Revenue Market Share by Region: 2020 VS 2024
Figure 14. North America Follicular Lymphoma Drugs Revenue (US$ Million) Growth Rate (2020-2031)
Figure 15. Europe Follicular Lymphoma Drugs Revenue (US$ Million) Growth Rate (2020-2031)
Figure 16. China Follicular Lymphoma Drugs Revenue (US$ Million) Growth Rate (2020-2031)
Figure 17. Japan Follicular Lymphoma Drugs Revenue (US$ Million) Growth Rate (2020-2031)
Figure 18. Global Follicular Lymphoma Drugs Market Share by Players in 2024
Figure 19. Global Top Follicular Lymphoma Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Follicular Lymphoma Drugs as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Follicular Lymphoma Drugs Revenue in 2024
Figure 21. North America Follicular Lymphoma Drugs Market Share by Type (2020-2025)
Figure 22. North America Follicular Lymphoma Drugs Market Share by Administration Route (2020-2025)
Figure 23. Europe Follicular Lymphoma Drugs Market Share by Type (2020-2025)
Figure 24. Europe Follicular Lymphoma Drugs Market Share by Administration Route (2020-2025)
Figure 25. China Follicular Lymphoma Drugs Market Share by Type (2020-2025)
Figure 26. China Follicular Lymphoma Drugs Market Share by Administration Route (2020-2025)
Figure 27. Japan Follicular Lymphoma Drugs Market Share by Type (2020-2025)
Figure 28. Japan Follicular Lymphoma Drugs Market Share by Administration Route (2020-2025)
Figure 29. Roche Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 30. Gilead Sciences Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 31. Beigene Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 32. Bayer Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 33. Secura Bio Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 34. Epizyme Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 35. Eisai Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 36. Acrotech Biopharma Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 37. Teva Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 38. Eagle Pharmaceuticals Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 39. MundiPharma Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 40. Pfizer Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 41. Novartis Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 42. Bristol-Myers Squibb Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 43. JW Therapeutics Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 44. FOSUNKite Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 45. Bottom-up and Top-down Approaches for This Report
Figure 46. Data Triangulation
Figure 47. Key Executives Interviewed
